for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merus NV

MRUS.OQ

Latest Trade

19.81USD

Change

-0.19(-0.95%)

Volume

1,217

Today's Range

19.81

 - 

20.00

52 Week Range

11.00

 - 

20.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.00
Open
20.00
Volume
1,217
3M AVG Volume
0.98
Today's High
20.00
Today's Low
19.81
52 Week High
20.88
52 Week Low
11.00
Shares Out (MIL)
23.39
Market Cap (MIL)
467.87
Forward P/E
-9.97
Dividend (Yield %)
--

Next Event

Q3 2019 Merus NV Earnings Release

Latest Developments

More

Merus NV Files Prospectus Relating To Proposed Resale Of 7.9 Million Common Shares

Merus NV Files For U.S. Mixed Shelf Of Up To $250 Million

Merus Announces Second Quarter Loss Per Share Of Eur 0.51

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merus NV

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Industry

Biotechnology & Drugs

Contact Info

Yalelaan 62

+31.30.2538800

https://www.merus.nl/

Executive Leadership

Mark T. Iwicki

Chairman of the Supervisory Board

Ton Logtenberg

Chief Executive Officer

John J. Crowley

Chief Financial Officer, Executive Vice President

Peter B. Silverman

Executive Vice President, General Counsel

Hui Liu

Chief Business Officer and Head of Merus U.S., Executive Vice President

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-2.120

2017

-3.800

2018

-1.090

2019(E)

-1.822
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.02
Price To Book (MRQ)
5.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.87
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-15.92
Return on Equity (TTM)
-13.60

Latest News

BRIEF-Merus Q4 Loss Per Share EUR 0.73

* MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017

BRIEF-Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration

* MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER Source text for Eikon: Further company coverage:

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

BRIEF-Merus Announces $55.8 Mln Private Placement Offering

* MERUS ANNOUNCES $55.8 MILLION PRIVATE PLACEMENT OFFERING OF COMMON STOCK

BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs

* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS

BRIEF-Merus Nv Q3 Loss Per Share Eur 0.81

* MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS

BRIEF-Merus announces Q2 loss per share EUR 1.12

* Merus announces second quarter 2017 financial results and highlights recent progress

BRIEF-U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against Regeneron

* Says U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against regeneron

BRIEF-Merus Q1 loss per share EUR 1.15

* Merus announces first quarter 2017 financial results and mid-year operating results

BRIEF-Merus announces results from MCLA-128 phase 1/2 study

* Merus announces promising results from MCLA-128 phase 1/2 study in metastatic breast cancer

BRIEF-Merus reports Q4 loss per share eur 1.91

* Merus announces fourth quarter and full year 2016 financial results and corporate developments

BRIEF-Aglaia Oncology Fund B.V. reports 6.9 percent passive stake in Merus Nv as of December 31, 2016

* Aglaia Oncology Fund B.V. Reports a 6.9 percent passive stake in Merus Nv as of December 31, 2016 - SEC filing Source text : [ID:http://bit.ly/2kdQTdh] Further company coverage:

BRIEF-Merus announces closing of global strategic research collaboration with Incyte

* Merus announces closing of global strategic research collaboration with Incyte to discover and develop bispecific antibodies

BRIEF-Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016

* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing Source text: (http://bit.ly/2j9ZI8k) Further company coverage:

BRIEF-Merus announces Q3 loss per share of eur 0.31

* Merus announces third quarter 2016 financial results and corporate developments

BRIEF-Merus appoints L. Sirulnik as chief medical officer

* Merus expands executive management team with the appointment of L. Andres Sirulnik, MD, PHD, as chief medical officer Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up